Current position of viral load versus hepatitis C core antigen testing.

Posición actual de la carga viral frente a la determinación de antígeno core del virus de la hepatitis C.
Antígeno core Carga viral Core antigen Diagnosis Diagnóstico Hepatitis C Tratamiento Treatment Viral load

Journal

Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541

Informations de publication

Date de publication:
Jan 2020
Historique:
entrez: 1 3 2020
pubmed: 1 3 2020
medline: 30 7 2021
Statut: ppublish

Résumé

Quantification of hepatitis C virus (HCV) RNA (viral load) is the most widely used marker to diagnose and confirm active HCV infection. The HCV core antigen forms part of the internal structure of the virus and, like HCV RNA, its detection also indicates viral replication and presents certain advantages over viral load testing such as its lower cost, the greater stability of the target, the possibility of working with the same primary tube as that used for HCV serology, and the rapidity of obtaining results, since there is no need to work in batches, unlike the situation with most viral load platforms. Although the core antigen has lower analytical sensitivity than HCV RNA for the detection of low viremia levels, several studies and guidelines have already shown their utility in the identification of patients with active HCV infection. This article summarises current platforms for viral load determination, including point-of-care systems, and also reviews the indications attributed to this marker by the main HCV treatment guidelines. The article also reviews the characteristics of HCV core antigen, the available platforms for its determination, its correlation with viral load determination, and the indications for this marker in the distinct guidelines.

Identifiants

pubmed: 32111360
pii: S0213-005X(20)30033-1
doi: 10.1016/j.eimc.2020.02.003
pii:
doi:

Substances chimiques

Hepatitis C Antigens 0
RNA, Viral 0
Viral Core Proteins 0
nucleocapsid protein, Hepatitis C virus 0

Types de publication

Journal Article Review

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

12-18

Informations de copyright

Copyright © 2020. Publicado por Elsevier España, S.L.U.

Auteurs

Antonio Aguilera (A)

Servicio de Microbiología, Complejo Hospitalario Universitario de Santiago de Compostela y Departamento de Microbiología de la Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, España.

Juan Carlos Alados (JC)

Servicio de Microbiología, Hospital Universitario de Jerez, Jerez, Cádiz, España.

Roberto Alonso (R)

Servicio de Microbiología, Hospital Universitario Gregorio Marañón, Madrid, España.

José María Eiros (JM)

Servicio de Microbiología, Hospital Universitario Río Hortega, Valladolid, España.

Federico García (F)

Servicio de Microbiología, Hospital Universitario San Cecilio, Granada, España; Instituto de Investigación Biosanitaria Ibs.Granada, Granada, España. Electronic address: fegarcia@ugr.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH